Product Use Citations
-
Fernández ML, et al. Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Am J Cancer Res. 2016, 6(10):2235-2251.
Binimetinib (MEK162, ARRY-162, ARRY-438162) , Refametinib (RDEA119, Bay 86-9766) purchased from Selleck.
-
Li K, et al. Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology.
Med Oncol. 2016, 33(7):64.
Letrozole purchased from Selleck.
-
Yang P, et al. Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.
Sci Rep. 2016, 6:35444.
Refametinib (RDEA119, Bay 86-9766) purchased from Selleck.
-
Tuscher JJ, et al. Inhibition of local estrogen synthesis in the hippocampus impairs hippocampal memory consolidation in ovariectomized female mice.
Horm Behav. 2016, 83:60-7.
Letrozole purchased from Selleck.
-
Ru X, et al. Transient receptor potential channel M2 contributes to neointimal hyperplasia in vascular walls.
Biochim Biophys Acta. 2015, 10.1016/j.bbadis.2015.03.014.
R428 (BGB324) purchased from Selleck.
-
Yin H, et al. Adenovirus-mediated TIPE2 overexpression inhibits gastric cancer metastasis via reversal of epithelial-mesenchymal transition.
Cancer Gene Ther. 2017, 24(4):180-188.
AR-A014418 purchased from Selleck.
-
Tosello V, et al. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
Oncotarget. 2016, 7(29):45715-45729.
Salubrinal , GSK650394 purchased from Selleck.
-
Hsu CW, et al. Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling.
Oncotarget. 2016, 7(7):8172-83.
TAK-632 purchased from Selleck.
-
Song Y, et al. Advanced glycation end products regulate anabolic and catabolic activities via NLRP3-inflammasome activation in human nucleus pulposus cells.
J Cell Mol Med. 2017, 10.1111/jcmm.13067.
-
Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
Oncotarget. 2016, 7(25):37966-37978.
LMK-235 purchased from Selleck.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
AllPage:
Page:
